Volume 3 Supplement 1

2006 International Meeting of The Institute of Human Virology

Open Access

Anti-CD4-gp120 complex antibodies in long-term non-progressors HIV-1 positive patients: a role in slowing disease progression?

  • Samuele Burastero1,
  • Claudio Casoli2,
  • Chiara Paolucci1,
  • Paola Breda1,
  • Chiara Alberti1,
  • Claudia Pastori1 and
  • Lucia Lopalco1
Retrovirology20063(Suppl 1):P36

DOI: 10.1186/1742-4690-3-S1-P36

Published: 21 December 2006

Background

Exposure to HIV-1 does not necessarily result in infection and progression toward disease. Discovery of individuals who, despite multiple exposures to HIV remain uninfected (ESN) or do not progress toward disease (Long term Non Progressors) (LTNP), have confidently revealed that the better control of viral infection may be achieved through mechanisms of natural resistance. Antibodies (Abs) to CD4/gp120 complex have been detected in ESN, which could be involved in HIV protection.

Materials and methods

To assess whether these Abs may also contribute to slow HIV-disease progression, we searched for anti-CD4/gp120 complex Abs in 132 subjects, including 72 Long Term Non Progressors (LTNP), 30 Fast Progressors, and 30 seronegative donors.

Results

We found that these antibodies are present at higher titers in LTNP as compared to Fast Progressors (p < 0,001). In single patients, an association between the presence of CD4/gp120 complex antibodies and neutralizing activity against R5 dependent strains was found. Noteworthy, competition with soluble CD4 prevalently inhibited binding to CD4-gp120 complex in LTNP (-46,0% [60,9–34,8 IQR]) as compared to FP (-12,7% [33,7–5,4 IQR])(p < 0,001), further suggesting a major contribution of anti-complex antibodies in the anti-CD4 activity detected in the former. As these antibodies recognize conformational epitopes within the CD4/gp120 complex, they may be involved in modulation of HIV entry process.

Conclusion

These antibodies could represent a marker of disease progression. Moreover, our finding could be relevant for vaccine design and therapeutics.

Authors’ Affiliations

(1)
Infectious Diseases Clinic, San Raffaele Scientific Institute
(2)
Department of Clinical Medicine and Nephrology, University of Parma

Copyright

© Burastero et al; licensee BioMed Central Ltd. 2006

This article is published under license to BioMed Central Ltd.

Advertisement